However, our review extends these observations by demonstrating how specific interventions, like the use of GLP-1 receptor agonists and surgical options such as SASI bypass and LRYGB, modulate these pathophysiological factors, offering therapeutic benefits beyond typical GERD and diabetes management [14]. The gene discussed is GLP1R; the disease is gastroesophageal reflux disease.